Aydemir Selim, Aydın Sidar Şiyar, Aksakal Emrah, Altınkaya Onur, Özmen Murat, Birdal Oğuzhan
Department of Cardiology, University of Health Sciences, Erzurum City Hospital, Erzurum, Turkey.
Department of Cardiology, Atatürk University Faculty of Medicine, Erzurum, Turkey.
BMC Cardiovasc Disord. 2024 Dec 31;24(1):760. doi: 10.1186/s12872-024-04454-1.
Diabetes mellitus (DM) and atrial Fibrillation (AF) are among the most common health issues. They are responsible for the highest rates of morbidity and mortality. The importance of sodium glucose cotransporter-2 inhibitors (SGLT-2is) in treating DM has increased significantly in recent years. In our article, we aimed to evaluate the effect of SGLT-2i on the clinical outcomes of AF patients with DM.
Our study is a retrospective, observational study. The patients with AF and DM were divided into two groups: those using SGLT-2i or not using SGLT-2i, and 3-year follow-up results were examined. The endpoints of the study were defined as all-cause death, the development of myocardial infarction (MI), major bleeding requiring hospitalization, and an ischemic cerebrovascular event (CVE). Differences between groups according to SGLT-2i use were analyzed.
The study included 485 patients, 205 (42.3%) of whom were male and had an average age of 70.7 ± 9.7 years. A total of 138 of 485 patients (28.5%) received SGLT-2i. All-cause mortality was lower in the group receiving SGLT-2i (p < 0.001). Similarly, a significant reduction in major bleeding events was observed among those who received SGLT-2i treatment (p = 0.009). The incidence of CVEs was lower among SGLT-2i recipients, but the difference was not statistically significant (p = 0.066). SGLT2i usage did not mitigate the risk of MI development (p = 0.317).
In our study, SGLT-2i treatment was associated with a significant reduction in all-cause mortality and major bleeding in diabetic AF patients. Our study provides evidence of the clinical benefit of SGLT-2i in AF patients.
糖尿病（DM）和心房颤动（AF）是最常见的健康问题。它们导致了最高的发病率和死亡率。近年来，钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）在治疗糖尿病中的重要性显著增加。在我们的文章中，我们旨在评估SGLT-2i对糖尿病合并房颤患者临床结局的影响。
我们的研究是一项回顾性观察性研究。将房颤合并糖尿病患者分为两组：使用SGLT-2i组和未使用SGLT-2i组，并对3年随访结果进行检查。研究终点定义为全因死亡、心肌梗死（MI）的发生、需要住院治疗的大出血以及缺血性脑血管事件（CVE）。分析了根据SGLT-2i使用情况分组之间的差异。
该研究纳入了485例患者，其中205例（42.3%）为男性，并平均年龄为70.7±9.7岁。485例患者中有138例（28.5%）接受了SGLT-2i治疗。接受SGLT-2i治疗的组全因死亡率较低（p<0.001）。同样，在接受SGLT-2i治疗的患者中观察到大出血事件显著减少（p=0.009）。SGLT-2i接受者中CVE的发生率较低，但差异无统计学意义（p=0.066）。使用SGLT-2i并不能降低MI发生的风险（p=0.317）。
在我们的研究中，SGLT-2i治疗与糖尿病房颤患者全因死亡率和大出血的显著降低相关。我们的研究提供了SGLT-2i对房颤患者临床益处的证据。
